Literature DB >> 5481518

Spironolactone diuresis in patients with cirrhosis and ascites.

R C Eggert.   

Abstract

Increased aldosterone levels with consequent or diuretic-potentiated electrolyte abnormalities are an important consideration when patients with cirrhosis and ascites undergo diuresis. A simple clinical method using the urinary Na/K ratio as a guide to spironolactone dosage is outlined. Patients with a ratio greater than 1 responded well to 100 mg. of spironolactone a day; those when it was one or less responded well to 200 to 1,000 mg. a day.Administration of spironolactone alone (11 patients) or as the main diuretic (three patients) was a safe and effective means of inducing sustained uncomplicated diuresis in all these patients.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5481518      PMCID: PMC1819973          DOI: 10.1136/bmj.4.5732.401

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  11 in total

1.  BODY AND SERUM POTASSIUM IN LIVER DISEASE. I. RELATIONSHIP TO HEPATIC FUNCTION AND ASSOCIATED FACTORS.

Authors:  T H CASEY; W H SUMMERSKILL; A L ORVIS
Journal:  Gastroenterology       Date:  1965-02       Impact factor: 22.682

2.  Significance of aldosterone antagonism in the treatment of edema and ascites.

Authors:  C L GANTT; R E ECKLUND
Journal:  Am J Med       Date:  1962-10       Impact factor: 4.965

3.  Human assay of electrolyte-active steroids and their antagonists.

Authors:  E J ROSS
Journal:  Clin Sci       Date:  1962-10       Impact factor: 6.124

4.  The metabolism of aldosterone in normal subjects and in patients with hepatic cirrhosis.

Authors:  W S COPPAGE; D P ISLAND; A E COONER; G W LIDDLE
Journal:  J Clin Invest       Date:  1962-08       Impact factor: 14.808

5.  Exchangeable potassium in wasting, amyotrophy, heart-disease, and cirrhosis of the liver.

Authors:  C NAGANT DE DEUXCHAISNES; R A COLLET; R BUSSET; R S MACH
Journal:  Lancet       Date:  1961-04-01       Impact factor: 79.321

6.  A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents.

Authors:  D A OGDEN; L SCHERR; N SPRITZ; A L RUBIN
Journal:  N Engl J Med       Date:  1961-08-24       Impact factor: 91.245

7.  Sodium diuresis induced by steroidal antagonists of aldosterone.

Authors:  G W LIDDLE
Journal:  Science       Date:  1957-11-15       Impact factor: 47.728

8.  Complications of diuretic therapy in hepatic cirrhosis.

Authors:  S Sherlock; B Senewiratne; A Scott; J G Walker
Journal:  Lancet       Date:  1966-05-14       Impact factor: 79.321

9.  The use of ethacrynic acid in patients with cirrhosis and ascites.

Authors:  F L Lieberman; T B Reynolds
Journal:  Gastroenterology       Date:  1965-11       Impact factor: 22.682

10.  Electrolyte excretion during the spontaneous recovery from the ascitic phase of cirrhosis of the liver.

Authors:  R Pecikyan; G Kanzaki; E Y Berger
Journal:  Am J Med       Date:  1967-03       Impact factor: 4.965

View more
  14 in total

Review 1.  Diuretics: mechanism of action and clinical application.

Authors:  D L Davies; G M Wilson
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Renal retention of sodium in cirrhosis and fulminant hepatic failure.

Authors:  S P Wilkinson; H Moodie; A Alam; R Williams
Journal:  Postgrad Med J       Date:  1975-08       Impact factor: 2.401

Review 4.  Pathogenesis of ascites and hepatorenal syndrome.

Authors:  S P Wilkinson; K P Moore; V Arroyo
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

5.  Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites.

Authors:  J L Campra; T B Reynolds
Journal:  Am J Dig Dis       Date:  1978-11

6.  The hepatorenal syndrome revisited.

Authors:  S P Wilkinson
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

7.  Clinical and hormonal conditions associated with sodium retention in cirrhotic patients with ascites. Evaluation by univariate and multivariate analyses.

Authors:  S Gentile; M Angelico; M G Chiappini; G Peruzzi; S Vulterini
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

8.  The kidney and liver diseases.

Authors:  S P Wilkinson
Journal:  J Clin Pathol       Date:  1981-11       Impact factor: 3.411

9.  The urinary sodium: potassium ratio and response to diuretics in resistant oedema.

Authors:  W D Alexander; R A Branch; D F Levine; M Hartog
Journal:  Postgrad Med J       Date:  1977-03       Impact factor: 2.401

Review 10.  Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.

Authors:  Sara S Roscioni; Dick de Zeeuw; Stephan J L Bakker; Hiddo J Lambers Heerspink
Journal:  Nat Rev Nephrol       Date:  2012-10-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.